Compare Denver Biomedical vs Micrus Endovascular
Customers evaluate the quality of Denver Biomedical's products using the following success metrics.
Overview
Denver Biomedical is 55 yrs old and is based in United States.
Denver Biomedical, Inc., a manufacturer, distributor and marketer of disposable medical devices for the outpatient management of recurrent malignant pleural effusions (MPE), was acquired by Cardinal Health, Inc. (NYSE: CAH) in May 2006.
Micrus Endovascular is 28 yrs old and is based in United States.
Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus is developing products for the treatment of hemorrhagic and ischemic stroke. Both hemorrhagic and ischemic stroke are significant causes of death worldwide. Micrus product lines consist of endovascular systems that enable a physician to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus also sells accessory devices and products used in neurovascular procedures.
Demo Video
Leadership
Duane Knight (Chief Financial Officer)
Eckhard H Reitz (Executive Vice President)
Investors
Cardinal Health and CID Capital
Johnson & Johnson, Aventic Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Denver Biomedical has not claimed their profile.
Work for Denver Biomedical? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Denver Biomedical?
Claim your profile now.
Information not available because Micrus Endovascular has not claimed their profile.
Work for Micrus Endovascular? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Micrus Endovascular?
Claim your profile now.